Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy